Evotec SE
ISIN: DE0005664809 | Ticker: EVT
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this "Data-driven R&D Autobahn to Cures" for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases.
Year founded1993
Served areaWorldwide
Headcount3,030
HeadquartersEssener Bogen 7, 22419 Hamburg – Germany
| Date | Trading entity / Person | Association | Trade type | Volume | Average price |
|---|---|---|---|---|---|
| 20.01.23 | Lanthaler, Dr. Werner | Board | Other | 467,992.56 € | 20.01.23 |
| 20.01.23 | Dohrmann, Dr. Cord | Board | Other | 110,412.51 € | 20.01.23 |
| 20.01.23 | Johnstone, Dr. Craig | Board | Other | 173,397.70 € | 20.01.23 |
| 20.01.23 | Johnstone, Dr. Craig | Board | Other | 173,415.65 € | 20.01.23 |
| 20.01.23 | Spillner, Enno | Board | Other | 114,737.13 € | 20.01.23 |
| 20.01.23 | Spillner, Enno | Board | Other | 114,737.13 € | 20.01.23 |
| 20.01.23 | Lanthaler, Dr. Werner | Board | Other | 468,010.50 € | 20.01.23 |
| 20.01.23 | Dohrmann, Dr. Cord | Board | Other | 165,627.74 € | 20.01.23 |
| 18.01.23 | Gurdal, Hakan | Board | Buy | 493,900.00 € | 18.01.23 |
| 14.06.22 | Lanthaler, Dr. Werner | Board | Buy | 226,873.95 € | 14.06.22 |
| 14.06.22 | Lanthaler, Dr. Werner | Board | Buy | 228,559.35 € | 14.06.22 |
| 14.06.22 | Wagner, Wolfgang | Board | Buy | 7,750.00 € | 14.06.22 |
| 25.01.22 | Polywka, Dr. Mario | Supervisory board | Other | 422,459.56 € | 25.01.22 |
| 25.01.22 | Polywka, Dr. Mario | Supervisory board | Other | 424,653.60 € | 25.01.22 |
| 25.01.22 | Johnstone, Dr. Craig | Board | Other | 145,479.25 € | 25.01.22 |
| 25.01.22 | Johnstone, Dr. Craig | Board | Other | 145,514.63 € | 25.01.22 |
| 25.01.22 | Dohrmann, Dr. Cord | Board | Other | 444,930.81 € | 25.01.22 |
| 25.01.22 | Dohrmann, Dr. Cord | Board | Other | 447,266.40 € | 25.01.22 |
| 25.01.22 | Spillner, Enno | Board | Other | 369,873.29 € | 25.01.22 |
| 25.01.22 | Spillner, Enno | Board | Other | 371,819.61 € | 25.01.22 |
| 25.01.22 | Lanthaler, Dr. Werner | Board | Other | 1,508,865.02 € | 25.01.22 |
| 25.01.22 | Lanthaler, Dr. Werner | Board | Other | 1,516,614.94 € | 25.01.22 |
| 04.01.22 | Lanthaler, Dr. Werner | Board | Buy | 392,479.78 € | 04.01.22 |
| 02.09.21 | Matador Partners Group AG | Close relation | Sell | 7,846,965.00 € | 02.09.21 |
| 02.09.21 | ELF Partners Group AG | Close relation | Buy | 7,846,965.00 € | 02.09.21 |
| 01.09.21 | Dohrmann, Dr. Cord | Board | Other | 447,881.52 € | 01.09.21 |
| 01.09.21 | Polywka, Dr. Mario | Supervisory board | Other | 865,612.68 € | 01.09.21 |
| 01.09.21 | Dohrmann, Dr. Cord | Board | Other | 440,025.44 € | 01.09.21 |
| 01.09.21 | Lanthaler, Dr. Werner | Board | Other | 1,518,813.92 € | 01.09.21 |
| 01.09.21 | Ceccaldi-Weng, Maximilien | Close relation | Sell | 15,300.00 € | 01.09.21 |
| 01.09.21 | Lanthaler, Dr. Werner | Board | Other | 1,492,060.78 € | 01.09.21 |
| 01.09.21 | Spillner, Enno | Board | Other | 372,335.75 € | 01.09.21 |
| 01.09.21 | Spillner, Enno | Board | Other | 365,796.09 € | 01.09.21 |
| 01.09.21 | Johnstone, Dr. Craig | Board | Other | 271,268.34 € | 01.09.21 |
| 01.09.21 | Johnstone, Dr. Craig | Board | Other | 271,225.87 € | 01.09.21 |
| 30.08.21 | Brandes, Dr. Jürgen | Board | Buy | 29,000.00 € | 30.08.21 |
176,952,653
IPOOct. 28, 2009
Designated Sponsor(s)Oddo BHF Corporates & Markets AG
Stock exchange(s)Frankfurt Stock Exchange